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Background. Lipoprotein (a) [Lp(a)] is an independent risk factor for cardiovascular disease (CVD) in Non-Hispanic Whites
(NHW). There are known racial/ethnic diﬀerences in Lp(a) levels, and the association of Lp(a) with CVD outcomes has not been
examined in Asian Americans in the USA. Objective. We hypothesized that Lp(a) levels would diﬀer in Asian Indians and Chinese
Americanswhen compared toNHW andthattherelationshipbetween Lp(a)andCVDoutcomes wouldbe diﬀerent in these Asian
racial/ethnicsubgroups whencompared to NHW.Methods.Westudied the outpatientelectronic health records of2022 NHW, 295
AsianIndians,and151Chineseadults age ≥ 18yinNorthern Californiain whomLp(a)levelswere assessedduringroutineclinical
care from 2001 to 2008, excluding those who had received prescriptions for niacin (14.6%).Nonparametric methods were used to
comparemedianLp(a) levels.Signiﬁcancewasassessedat theP<. 0001levelto accountformultiple comparisons.CVD outcomes
weredeﬁnedasischemicheartdisease(IHD)(265events),stroke(122),orperipheralvasculardisease(PVD)(87).Weusedlogistic
regression to determine the relationship between Lp(a) and CVD outcomes. Results. Both Asian Indians (36nmol/L) and NHW
(29nmol/L) had higher median Lp(a) levels than Chinese (22nmol/L, P ≤ .0001 and P = .0032). When stratiﬁed by sex, the
diﬀerences in median Lp(a) between these groups persisted in the 1761 men (AI v CH: P = .001, NHW v CH: P = .0018) but
were not statistically signiﬁcant in the 1130 women (AI v CH: P = .0402, NHW v CH: P = .0761). Asian Indians (OR = 2.0)
and Chinese (OR = 4.8) exhibited a trend towards greater risk of IHD with high Lp(a) levels than NHW (OR = 1.4), but no
relationship was statistically signiﬁcant. Conclusion. Asian Indian and NHW men have higher Lp(a) values than Chinese men,
with a trend toward, similar associations in women. High Lp(a) may be more strongly associated with IHD in Asian Indians and
Chinese, although we did not have a suﬃcient number of outcomes to conﬁrm this. Further studies should strive to elucidate the
relationship between Lp(a) levels, CVD, and race/ethnicity amongAsian subgroups in the USA.
1.Introduction
Lipoprotein (a) [Lp(a)] is an independent risk factor for
cardiovascular disease (CVD) [1–6]. Based on its structural
homology with plasminogen, Lp(a) is believed to increase
CVD incidence through an increased risk of vascular throm-
bosis. This mechanism diﬀers from that of other CVD-
related lipids, such as cholesterol [7, 8]. Lp(a) levels are
genetically determined (roughly one third of the variation in
levels is explained by genetics) [9–12]a n dd i ﬀer signiﬁcantly
by racial/ethnic group, for example, it is well established
that African Americans have higher Lp(a) levels than Whites
[13]. The distribution of Lp(a) levels in Asians in the USA
is less well characterized, particularly since many studies
have failed to distinguish between diverse Asian subgroups
(such as Asian Indians and Chinese). With CVD rates rising
in both native and immigrant Asians, characterizing the
distribution of Lp(a) levels in Asian racial/ethnic subgroups
and its relationship to CVD outcomes may aid eﬀorts to
reduce CVD risk in these populations [14].2 Journal of Lipids
The few studies that have made distinctions between
racial/ethnic groups have reported higher levels of Lp(a) in
Asian Indians compared with Chinese [15, 16]. However,
both of these studies were performed in small volunteer
samples (which may not reﬂect larger clinical populations)
and were performed prior to standardization of Lp(a)
assays, which makes their results less reliable [17–19]. Other
studies have also reported higher Lp(a) levels in Asian
Indians compared with Non-Hispanic Whites (NHW), but
the evidence is conﬂicting [20–22]. Lp(a) distributions also
diﬀer by gender, [1, 4] but no studies have examined
gender diﬀerences in the distribution of Lp(a) in diﬀerent
Asian subgroups. The association between Lp(a) levels and
CVD may also be modiﬁed by race: elevated Lp(a) levels
do not seem to confer the same increase in CVD risk
in African Americans compared to NHW [13], and the
association between Lp(a) and CVD in Chinese is equivocal
[23].
Taking advantage of a large multiethnic patient cohort
in a practice group that used standardized Lp(a) assays,
which reduce variability in Lp(a) results, we sought to
compare Lp(a) distributions in male and female Asian
Indians, Chinese, and Non-Hispanic Whites. We also sought
tocharacterize theassociationbetweenLp(a)levelsand CVD
in these racial/ethnic subgroups.
2.Methods
2.1. Setting. The Palo Alto Medical Foundation (PAMF) is
a mixed-payer, outpatient-focused healthcare organization
in the San Francisco bay area of Northern California that
includes over 300 physicians serving more than 400,000
active patients with large Asian Indian and Chinese popu-
lations (both 11%).
2.2. Inclusion/Exclusion. We examined the electronic health
records (EHR) of all adult (≥18 years) patients from January
1, 2001 to December 31, 2008. There were 2,891 NHW,
Asian Indian, or Chinese patients with at least one Lp(a)
result in the chart (drawn as part of routine clinical care).
Approximately 15% of those with an Lp(a) were also on
niacin and were excluded from the analysis since niacin low-
ers Lp(a) levels, leaving 2468 patients for analysis. The study
received approval from the Palo Alto Medical Foundation
Institutional Review Board on September 11, 2008.
2.3. Clinical Deﬁnitions. Low density lipoprotein cholesterol
(LDL-C), high density lipoprotein cholesterol (HDL-C),
total cholesterol, and triglyceride levels were obtained via
the EHR and date matched to lipoprotein (a) results. Pre-
scription for medication was used to determine medication
usageaspharmacyrecordswerenotavailable.Cardiovascular
events were deﬁned by an ICD-9 code on a regularly
maintained problem list or diagnosis from a speciﬁc patient
encounter. Ischemic heart disease (IHD, ICD-9: 410.X-
414.X) and cardiovascular disease (CVD, a composite of
IHD, PVD, and stroke, ICD-9: 410.X-414.X, 430.X-438.X,
443.X) were deﬁned accordingly.
3.LaboratoryMethods
Lp(a) consists of LDL-C bound to apolipoprotein (a) via
apolipoprotein B-100 in a 1:1 Molar ratio. Apolipoprotein
(a) carries a region called the K4 type II repeat sequence,
or kringle repeat, and the number of repeats of the kringle
sequence is genetically determined and variable. Lp(a) levels
were measured using a Quest immunoturbidmetric assay
(Polymedco, USA) shown to be independent of apolipopro-
tein (a) size; an Lp(a) value >75nmoL/L was considered
abnormal. Other Lp(a) assays use an antibody directed at
the K4 type II repeat sequence (the kringle sequence) and,
thus,will tendtounder-oroverestimateLp(a)concentration
based on the isoform of apolipoprotein (a) used to calibrate
the machine. Roughly 30% of the clinically available Lp(a)
values were obtained using a Vertical Auto Proﬁle assay
(Atherotech, USA), but these results were not used due to
the variability of this assay (antibody directed at kringle
sequence) and the uncertainty of converting these results
(mg/dL) into nmoL/L, which cannot be standardized due
to heterogeneity in LDL-C particle size (apolipoprotein (a)
isoform).Totalcholesterol,LDL-C,HDL-C,andtriglycerides
were measured by spectrophotometry using a Siemens
Dimension RxL analyzer (Siemens Healthcare Diagnostics,
USA). HDL and triglycerides were measured via a direct
method, while LDL-C was calculated using the Friedewald
equation LDL-C = [TC-HDL-C-(TRIG/5)]. All laboratory
measurements were carried out immediately on fresh blood
samples.
4.StatisticalAnalysis
We employed a cross-sectional analysis to examine Lp(a)
distributions stratiﬁed by race/ethnicity and gender. We also
investigated the association between Lp(a) levels and CVD
outcomes (ischemic heart disease, stroke, and peripheral
vascular disease), stratiﬁed by race/ethnicity and gender.
4.1. Univariate. Patient characteristics were described using
means, medians, and proportions. Diﬀerences in propor-
tions were evaluated using the Chi-square test. Normality
wasevaluatedbythequantile-quantileplotsandtheShapiro-
Wilk test of normality. Due to nonnormality of many of the
measures,includingLp(a),nonparametric testswereusedfor
statistical inference including Kruskal-Wallis, Wilcoxon, and
Brown-Mood median tests.
4.2. Multivariate. We sought to determine the relation-
ship between Lp(a) levels and CVD outcomes across
race/ethnicity adjusting for known risk factors. We built
logistic regression modeling CVD outcomes for each
race/ethnicity. Lipoprotein (a) was divided into quintiles,
a n dw ec o m p a r e dt h ep r e v a l e n c eo fC V Da n dI H Di nt h e
top quintile with the bottom four quintiles, adjusting for
age, gender, and HDL and LDL levels. Total cholesterol
or triglyceride levels were highly correlated with LDL and
HDL levels, respectively, and thus were not included in the
regression models.Journal of Lipids 3
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Figure 1: Median Lipoprotein (a) concentration by racial/ethnic
group and interquartile range (25th–75th percentile).
4.3. Sensitivity. As a sensitivity analysis, we analyzed the
relationshipbetweenniacinuseandLp(a)levels.Werepeated
the multivariate analysis on a sample including patients that
were initially excluded for niacin use and included niacin
usage in regression models as appropriate.
Signiﬁcance was assessed at the P<. 0001 level
employinga Bonferroni correctionformultiplecomparisons
undertaken during the analyses. All analyses were performed
using SAS 9.2 (Cary, NC, USA).
5.Results
Table 1 displays the demographic and risk factor character-
istics of our cohort, stratiﬁed by gender and race/ethnicity.
Approximately 1.2% of NHW, 2.0% of Asian Indians, and
0.7% of Chinese Americans had their Lp(a) determined in
this clinical cohort. Most clinical parameters were similar,
but Asian Indian men and women were younger and
exhibited lower HDL levels than their counterparts. When
comparing Lp(a) levels between NHW, Asian Indians, and
Chinese (Figure 1), there was a signiﬁcant overall diﬀerence
in median Lp(a) levels across all groups (P<. 0001), as
well as between Asian Indians and Chinese (P = .0001). In
contrast, there was no signiﬁcant diﬀerence between NHW
and Chinese (P = .0032) or NHW and Asian Indians (P =
.0085).
This pattern of higher median levels of Lp(a) in Asian
Indians and NHW compared to Chinese was the same
for both men and women (Table 2). In women, overall
diﬀerences between the groups were observed but did not
achievestatisticalsigniﬁcance attheP<. 0001level(Kruskal-
Wallis, P = .1642). In men, however, the overall diﬀerences
did achieve statistical signiﬁcance (P<. 0001) with Asian
Indians speciﬁcally having a signiﬁcantly higher median
value compared to Chinese (P = .0001)and a higher median
compared to NHW that was not quite statistically signiﬁcant
(P = .0086). Chinese had lower median values compared
to NHW, but again the diﬀerence was not quite statistically
signiﬁcant (P = .0018).
There was no signiﬁcant univariate association between
Lp(a)levelsandCVDevents(381)inanyracial/ethnicgroup.
Our multivariate analysis revealed that in the overall cohort,
there was no relationship between elevated Lp(a) (5th
quintile89nmoL/L and above)and IHDorCVD(composite
outcome)afteradjustingforage,gender,race/ethnicity,BMI,
LDL, and HDL (data not shown). For each racial/ethnic
group, having a Lp(a) value in the highest quintile was
associated with higher, but not statistically signiﬁcant, odds
of IHD (OR: 2.04 Asian Indian, and OR: 4.83 Chinese, OR:
1.37 NHW). When CVD was considered as an outcome,
the same elevated but not statistically signiﬁcant association
was observed for each racial/ethnic group (OR: 1.63 Asian
Indian, OR: 3.47 Chinese, and OR: 1.28 NHW) (Table 3).
Median levels of Lp(a) were higher in Asian Indians with
either CVD (64.5nmoL/L) or IHD (64nmoL/L) when
compared to NHW (30, 32) or Chinese (29, 29) with CVD
or IHD, respectively.
Sensitivity analyses were performed by including the
subset of patients who were treated with niacin. Of those
who had Lp(a) measured, 14.6 % (423) received a prescrip-
tion for niacin. A niacin prescription was more common
among men compared to women (18.7% versus 8.3%, P<
.0001) and more common in patients with abnormal Lp(a)
(>75nmol/L) compared to normal Lp(a) (11.9 versus 6.0%,
P<. 0001). When niacin use was included in logistic
regressionmodelsmodelingCVDoutcomesadjustingforthe
same aforementioned covariates, there was a positive, but
still not statistically signiﬁcant, association between niacin
use and CVD outcomes. There was a similar positive, not
statistically signiﬁcant, association between niacin use and
IHD outcomes.
6.Discussion
In this multiethnic study, our major ﬁnding was that
Lp(a) levels diﬀered between NHW, Asian Indians, and
Chinese. These patterns were similar in men and women;
the diﬀerences did not quite reach statistical signiﬁcance in
women, but this is likely due to the smaller sample size
and larger variability in Lp(a) levels. In addition, we report
that Lp(a) levels are associated with a higher prevalence of
IHD and CVD in Asian Indians and Chinese although this
association, limited by a small number of events, was not
statistically signiﬁcant.
This is not the only study to show that Lp(a) levels diﬀer
signiﬁcantly between these three racial/ethnic groups, with
investigators in Singapore also ﬁnding higher Lp(a) levels in
Asian Indian than Chinese newborns [16]a n dt h eS H A R E
study in Canada ﬁnding higher Lp(a) levels in Asian Indians
than Chinese adults [15]. However, the SHARE study also
found signiﬁcantly higher Lp(a) levels in Asian Indians than
NHW, while a previous study from Michigan found that
Asian Indian women exhibited signiﬁcantly higher levels of
Lp(a) than NHWwomen [24]. While ourstudy corroborates
the signiﬁcant diﬀerence in Lp(a) levels between Asian
Indians and Chinese cohorts, the discrepancy between our4 Journal of Lipids
Table 1: Patient characteristics by race/ethnicity and gender.
Male Female
NHW Asian Chinese NHW Asian Chinese
Indian Indian
N 1,126 213 93 896 82 58
Age (years)
M,F 54.1(13.2) 43.1 (8.6)‡ 51.5 (12.7) 56.7 (12.4) 44.2 (8.7)‡ 55 (13.2)
BMI (kg/m2)
M 27.0 (3.8) 25.9 (3.7) 25.4 (3.5) 25.9 (4.7) 26.1 (4.7) 23.3 (3.0)
Lipids (mg/dL)
Total cholesterol
F 200 (40) 199 (35) 199 (41) 213 (43) 187 (31)‡ 218 (40)
LDL cholesterol 123 (35) 123 (30) 120 (37) 124 (38) 110 (27) 129 (36)
HDL cholesterol
MF 52 (13) 45 (10)‡ 51 (12) 66 (18) 53 (13) 65 (17)
Triglycerides
M 126 (76) 156 (82) 158 (113) 114 (70) 117 (55) 120 (67)
Prevalence (%, events)
Diabetes 5.6% (63) 9.4% (20) 6.5% (6) 7.2% (64) 19.5% (16) 10.3% (6)
Cardiovascular disease
M 19.4% (218) 6.1% (13) 17.2% (16) 14.2% (127) 3.7% (3) 6.9% (4)
Ischemic heart disease 14.5% (163) 5.2% (11) 15.1% (14) 8.0% (71) 2.4% (2) 6.9% (4)
Stroke 6.2% (70) 0.9% (2) 4.3% (4) 5.2% (46) 0.0% (0) 0.0% (0)
Peripheral vascular disease 3.6% (40) 0.0% (0) 2.2% (2) 4.8% (43) 1.2% (1) 1.7% (1)
All continuous variables listed as mean (SD).
NHW: Non-Hispanic White.
M,FKruskal-Wallisor Chi-square test P<. 0001 for men or women, respectively.
‡Brown-Mood P<. 0001 for signiﬁcant diﬀerence in median between this group and each of the other two racial groups. Both pairs of comparisons are
signiﬁcant.
Table 2: Lp(a) summary results by sex and race/ethnicity.
Male Female
(N) NHW (1126) Asian Chinese (93) NHW (896) Asian Chinese (58)
Indian (213) Indian (82)
Lp(a) (nmol/L)
Median
M 27 35 19 34 41 27
Percent in highest quintile 18% 22% 10% 24% 26% 14%
Percent with Lp(a) > 75 22% 26% 11% 28% 28% 19%
NHW: Non-Hispanic White.
The highest quintileof Lp(a) was deﬁned for Lp(a) ≥ 89nmoL/L.
M,FKruskal-Wallisor Chi-square test P<. 0001 for men or women, respectively.
No group was signiﬁcantlydiﬀerent than the other two by pair-wise Brown-Mood tests of the median at P<. 0001.
Table 3: Multivariate adjusted odds ratio for association between
Lp(a) (top quintile versus bottom 4 quintiles) and CVD outcomes.
NHW Asian Chinese
Indian
Outcome (OR,
95% CI)∗
CVD 1.28 [0.80, 2.05] 1.63 [0.30, 9.00] 3.47 [0.24,
49.23]
IHD 1.37 [0.79, 2.37] 2.04 [0.31,
13.35]
4.83 [0.31,
75.30]
∗Adjusted for age, gender, BMI, LDL-C, and HDL-C.
results and previous results regarding Lp(a) levels in NHW
and Asian Indians has two possible explanations. First, the
discrepancy could be due to a lower sample size of Asian
Indians in our analysis compared with previous studies.
However,ourstudyincludedmoreAsianIndian womenthan
the Michigan study and a similar number of Asian Indians
compared to SHARE, making this hypothesis unlikely.
Alternatively, the assay used in our investigation, which does
not depend on Lp(a) isoform, could have reduced bias in the
determination of Lp(a) levels compared to previous assays,
which canoverestimate Lp(a)levelsin thepresenceofcertain
Lp(a) isoforms. The assay used in this study may lead to less
variation in Lp(a) levels, thus attenuating diﬀerences found
previously.
Others have noted an association between high levels
of Lp(a) and risk of IHD, particularly investigations that
used Lp(a) assays that are independent of isoform size and
that measured Lp(a) shortly after venipuncture. In these
studies, the risk for IHD due to elevated Lp(a) levels has
ranged from 1.4 to 1.6 in predominately NHW cohorts at
the 80th percentile of Lp(a) [5, 6, 12]. Gambhir et al., using
a case-control design, found that Asian Indians with knownJournal of Lipids 5
coronary artery disease (CAD) exhibited higher median
Lp(a) levels than controls [25]. In addition, both cases and
controlswith afamily history ofCADhad higherLp(a)levels
than thosewithouta family history ofCAD.Oneweakness of
this study was that the Lp(a) assay used was not independent
of apolipoprotein (a) size.
We similarly observed an increased risk of IHD for
those with higher Lp(a) levels (inclusion in the top quintile)
in our cohort of Asian Indians, Chinese, and NHW, but
the association was not statistically signiﬁcant. The lack of
statistical signiﬁcance may be due to the low occurrence of
IHD (265 cases) in our cohort; results may diﬀer in larger
cohorts or those with a higher prevalence of IHD and CVD.
High Lp(a) levels may account for a signiﬁcant portion of
the attributable risk for CVD in Asian Indians given the
particularly high levels of Lp(a) in Asian Indians with CVD
that we found, as compared to NHW and Chinese. If these
results are corroborated in larger studies, Asian Indians with
high Lp(a) levels may represent a group with particularly
high risk for CVD and should receive aggressive risk factor
reduction.
Niacin was frequently prescribed in this cohort of
patients with Lp(a) measured, and niacin prescription was
correlated with abnormal Lp(a) values. Niacin is the only
agent that has been shown to reduce Lp(a) levels. However,
this treatment was unequally applied by gender in our
cohort, with a higher proportion of men receiving niacin.
Such disparities need to be addressed if large-scale clinical
trials ﬁnd a reduction in CVDin patientswith elevatedLp(a)
level treated with niacin.
Strengths of our study include the assay used, which is
independent of Lp(a) isoform, determination of Lp(a) levels
without longstorage periods requiring freezing and thawing,
and a large representation of Asian Indians and Chinese
race/ethnicities.
Limitations include the cross-sectional analysis of exist-
ing clinical data, which limits conclusions regarding mea-
sures of association. There may have been selection bias such
that patients who were perceived to be at higher risk for
CVD events (i.e., Asian Indians) were sent for Lp(a) testing.
Theremayalsohavebeenreversecausation,wherethosewith
CVD were more likely to have Lp(a) measured, although
this would not be expected to produce higher Lp(a) levels in
those with CVD compared to those without who were also
measured. A major limitation was the relatively low number
ofcardiovascular events,especially in theAsian Indian group
(which was signiﬁcantly younger), limiting the power of the
study.
7.Conclusion
In conclusion, this cross-sectional analysis suggests that
Lp(a) levels diﬀer signiﬁcantly among Asian Indian, Chi-
nese, and Non-Hispanic White subgroups. The association
between Lp(a) and cardiovascular outcomes may diﬀer by
race/ethnicity as well, although we did not have a suﬃcient
number of CVD events to conﬁrm this. Further studies
should strive todisaggregate racial/ethnic groups and stratify
bygenderwhenexaminingLp(a)amongAsians.Ifreplicated,
our study suggests that determination of Lp(a) levels may be
particularly important in Asian Indians for the prevention of
cardiovascular disease.
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